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Previewsinteresting since the adult pancreas lacks
progenitor cells (Dor et al., 2004).
To investigate which SCFFbxw7 sub-
strates may play a role during b cell emer-
gence in the Fbxw7-deleted pancreas, the
authors analyzed a panel of four transcrip-
tion factors known to be involved in em-
bryonic b cell development and found
that both the mRNA and protein levels of
Ngn3, but not those of the other three,
were strongly increased in Fbxw7-deleted
pancreas. They then demonstrated that
knockdown of Fbxw7 reduced Ngn3
ubiquitination and increased Ngn3 protein
half-life. Fbxw7 binds to Ngn3 and this
binding, like the interactions between
many other F-box proteins and their sub-
strates, requires the GSK3b-mediated
phosphorylation of Ngn3 on two adjacent
serine residues, a characteristic feature
of phosphodegron motifs. Conditional
transgenic expression of a phosphode-
gron mutant Ngn3, in the presence of
endogenously expressed Fbxw7, quickly
(within 24 hr) resulted in the emergence
of insulin-positive b cells in the pancreas.
Together with the results from the
pancreas-conditional deletion of Fbxw7,
these findings suggest that the b cells
arise through direct conversion of ductal
cells rather than an intermediate progeni-
tor cell that divides prior to differentiation
(Sancho et al., 2014).112 Cell Stem Cell 15, August 7, 2014 ª2014Aside from identifying Fbxw7 as a regu-
lator of cell fate decision in both embry-
onic and adult pancreas and showing an
example of direct ductal-to-b cell con-
version, the study offers new evidence
consistent with the lack of stem/progeni-
tor cells in the adult pancreas. It also high-
lights the latent plasticity of mature adult
cells, which are generally viewed as termi-
nally differentiated. However, there are
two important issues that remain to be
determined. First, unlike most other E3
substrates whose mRNA levels remain
largely unchanged when the E3 function
is disrupted, the mRNA level of Ngn3 is
also increased in Fbxw7-deleted cells.
Although the authors propose a positive
feedback loop to explain this perplexing
phenomenon, both the direct evidence
supporting this loop and its significance
are yet to be demonstrated. Second,
Fbxw7 also degrades several additional
proteins that play a critical role in regu-
lating cell growth, proliferation, and fate
(Figure 1). Whether these proteins are
also regulated by Fbxw7 in the embryonic
and adult pancreas has not been exam-
ined. Does Fbxw7 control b cell neo-
genesis solely through Ngn3 or through
coordinated regulation of multiple sub-
strates? Ultimately, the in vivo induction
of functional b cells may be a viable treat-
ment option for patients with type 1 dia-Elsevier Inc.betes mellitus, and the current finding of
the SCF/CRL1Fbxw7-Ngn3 axis in control-
ling direct ductal-to-b cell conversion
offers a new target for this exploration.ACKNOWLEDGMENTS
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Although mesenchymal stem/stromal cells (MSCs) are an important component of the hematopoietic niche,
the markers that correlate with their physiological functions have not been defined. In this issue of Cell Stem
Cell, Zhou et al. (2014) identify the Leptin Receptor as a marker for prospective identification and in vivo fate
mapping of bone marrow MSCs.Mesenchymal stem/stromal cells (MSCs)
have been defined as nonhematopoietic,
plastic-adherent, colony-forming cellsthat are capable of in vitro trilineage
differentiation into fat, bone, and cartilage
(Pittenger et al., 1999). While MSCs canbe retrospectively identified based on
their ability to produce colony-forming
unit fibroblasts (CFU-Fs) in vitro, an
Figure 1. Correlation between LepR+ Cells and Distinct
Mesenchymal Markers in Bone Marrow
PDGFRa cells are derived from adult bonemarrow cells that can bemarked by
LepR. LepR+ cells include Sca-1 and Sca-1+ cells. PDGFRa+Sca-1+ cells,
which are PaS cells, are high efficiently CFU-F-forming cells. Conversely,
PDGFRa+Sca-1 cells secrete significant levels of CXCL12 and are a
subgroup of the CAR cells. There is a small portion of the PaS, CAR, and
LepR+ cells that overlaps with the Nestin-GFPlow (Low) cells, which are widely
expressed in many types of cells. MSC, mesenchymal stem cell; CAR cells,
CXCL12 (a chemokine)-abundant reticular cells.
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Previewsappropriate method for their
prospective identification was
lacking until very recently, and
their location and physio-
logical functions in vivo have
been elusive.
The lack of unique markers
and discrepancies arising
from the use of different line-
age tracing mouse strains
has contributed to the confu-
sion facing this field in the
past. The turning point in the
study of MSC markers was
the identification of PDGFRa
as a mesenchymal stem
cell marker. Mouse MSCs
are highly concentrated in
the CD45Ter119PDGFRa+
Sca-1+ (PaS) population
(Morikawa et al., 2009a).
In addition, PDGFRa+Sca-1
cells were found to secreteCXCL12 in the same manner as
CXCL12-abundant reticular (CAR) cells,
which are a key component of the niche
for hematopoietic stem cells (HSCs) in
adult bone marrow (BM) (Omatsu et al.,
2014). One report defined Nestin-GFP+
cells in the BM as ‘‘mesensphere’’-form-
ing cells that are required for maintenance
and homing of HSCs (Me´ndez-Ferrer
et al., 2010). Conversely, another group
reported that Nestin-GFP+ cells were
rarely CFU-F cells and were often non-
MSC populations (Ding et al., 2012).
Therefore, it is likely that the Nestin-GFP+
and PaS populations partially overlap but
are mostly distinct.
In this issue of Cell Stem Cell, Morrison
and colleagues identify the Leptin Recep-
tor (LepR), a receptor for a fat-cell-spe-
cific hormone that was expressed in
approximately 0.3% of BM cells (Zhou
et al., 2014), as an excellent marker for
the prospective identification of mouse
MSCs. Notably, 10% of LepR+ cells are
CFU-Fs, and they account for the vast
majority (94%) of CFU-Fs in adult mouse
BM. Furthermore, LepR+ cells in the limb
BM were uniformly positive for the MSC
marker Prx1.
This group also showed that LepR+
stromal and CAR cells, which are located
primarily around the sinusoids, are found
in a largely overlapping region (Omatsu
et al., 2010). They showed that LepR+
cells wereNestin-GFPlow. However, these
cells were negative for a Nestin-CreER-labeled marker (Nestin-CreER; loxp-
EYFP). This inconsistency can be inter-
preted as follows:Nestin-GFPlow, in which
GFP is regulated by the second intronic
enhancer of the Nestin gene, was re-
ported to serve as a marker for mesen-
chymal cells (Me´ndez-Ferrer et al.,
2010). However, Nestin-GFP expression
levels are not very high in MSCs, in
contrast to strong expression in neural
stem/progenitor cells, where expression
is putatively mediated by the action of
Brn2 and Sox2 on the Nestin second in-
tronic enhancer (Sunabori et al., 2008).
To our knowledge, transcription factors
acting on this enhancer have not yet
been identified in MSCs. Furthermore,
GFP is not knocked into the endogenous
Nestin gene in this model. Instead, its
expression is driven from a transgene
inserted into a chromosome. Thus,
the Nestin-GFP expression profile is
likely to be variable between the various
Nestin-GFP transgenic mouse lines. This
variability can account for the different
overlapping patterns between LepR
and Nestin-GFPlow or Nestin-CreER; loxp-
EYFP in the present study (Zhou et al.,
2014). Based on these findings, re-
searchers should carefully select Nestin
transgenic lines to mark MSCs.
As for CreER-mediated lineage tracing
experiments, it is important to appreciate
that different regimens of tamoxifen
could produce different results. Thus,
in order to label MSCs using NestinCell Stem Cell 15, August 7,transgenic lines, it is impor-
tant to use the appropriate
transgenic reporter line and
an appropriate induction
regimen that guarantees
robust recombination. The
Nestin protein expression
profile is more complicated
than the Nestin-driven trans-
gene expression because
the mesoderm-specific first
intronic enhancer is involved
in endogenous Nestin gene
expression. However, fortu-
nately for MSC researchers,
LepR-immunopositive cells
are also almost always Lepr-
Cre-labeled cells in BM
stroma (Zhou et al., 2014),
indicating that LepR is a reli-
able and versatile MSC
marker. Figure 1 illustrates
the relationships betweenvarious MSC markers in an effort to
synthesize findings from the present and
previous reports.
Furthermore, Zhou et al. (2014) per-
formed an excellent fate mapping study
of LepR+ cells. Using Lepr-Cre/loxp-
mediated lineage tracing, they showed
that during ontogenic development,
LepR+ cells appear postnatally in the
BM and are a major source of new
osteoblasts and adipocytes in adult
BM. As for the developmental origin of
MSCs, previous studies have shown
that prospective isolation of adult mouse
BM MSCs positive for PaS included
Wnt1-Cre- and P0-Cre-labeled, neural-
crest-marker-positive, neurosphere-initi-
ating units (Morikawa et al., 2009b), which
can also give rise to neurons, glial cells,
and myofibroblasts. Furthermore, Mori-
kawa et al. showed that CFU-Fs were
included in the P0-Cre-labeled and nonla-
beledPaS cells at a very similar frequency,
indicating that cells of the neural crest
origin could contribute to MSCs in adult
mouse BM. Conversely, Zhou et al.
(2014) surprisingly found that Wnt1-Cre-
labeled neural crest cells rarely included
CFU-Fs and thus are likely to be a distinct
population from the LepR+ BM cells.
These discrepancies could result from
differences in the transgenic Cre lines
used to mark neural crest cells or differ-
ences in other experimental conditions.
In any case, it would be interesting to
test whether a single MSC that has both2014 ª2014 Elsevier Inc. 113
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PreviewsCFU-F activity and neural crest character-
istics is present in adult mouse BM.
It is notable that LepR, a hormone re-
ceptor, is a marker of MSCs and that
LepR+ cells are involved in the regene-
rative response of bone and cartilage
after injury. Thus, an attractive idea is
that the fat-cell-specific hormone Leptin
and the LepR/Jak/STAT pathway, which
is blocked in db/db mice, play crucial
roles in the biological regulation (e.g.,
maintenance, proliferation, and/or differ-
entiation) of MSCs and the regenerative
responses of bone and cartilage. Thus,
the paracrine action of Leptin released
from BM adipocytes to the LepR+ MSCs
could possibly be involved in the homeo-
stasis of MSCs and MSCs-derived cells,
which should be elucidated in future
investigations.
The study of MSCs is likely to have
both biological significance and clinical
applications. In human MSCs, enriched
expression of the low-affinity nerve
growth factor receptor (LNGFR) (known
as a neural crest marker) has been repro-114 Cell Stem Cell 15, August 7, 2014 ª2014duced by many researchers (Mabuchi
et al., 2013), but the consistency of the
marker remains a problem. The next
step should be conducting comprehen-
sive analysis using LepR in multiple spe-
cies. By refining our ability to define
MSCs in vivo, the field may then shift
directions from markers to signaling
and focus on establishing MSC biology
in the near future.
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In this issue of Cell Stem Cell, Zhu et al. (2014) demonstrate that a genetically engineered glioma model
displays a functional cellular hierarchy defined by expression of the nuclear orphan receptor Tlx. Targeting
cancer stem cells through genetic deletion of TLX promotes cancer stem cell death and differentiation and
extends survival.Cancer is a genetic disease, but it initiates
and grows within a cellular context that
reflects the organization of tumors into
aberrant organ systems. The cellular
diversity within a tumor extends to the
neoplastic compartment in which genetic
and epigenetic variation manifests in dif-
ferential proliferation, survival, and migra-
tion of cancer cells. The cancer stem cell
(CSC) hypothesis is a partial explanation
for these observations because many
cancers harbor a relatively undifferenti-
ated pool of transformed cells that self-renew and propagate the entire range of
differentiated tumor progeny. However,
establishing the presence of cellular hier-
archies within a tumor and identifying
the origin of differentiated progeny is
complicated by the dynamic nature of
cancer and an inability to trace the history
of existing cancers. One challenge has
been the identification of reliable CSC sur-
face markers because these molecules
mediate interactions between cells and
their microenvironment and may be
dynamically changed after isolation ofCSCs. Further, no tumor type is geneti-
cally uniform, so markers are unlikely to
be uniformly informative in all tumors.
Tumor models derived from patient spec-
imens (e.g., patient-derived xenografts)
contain the cellular and molecular diver-
sity of the human disease but cannot
instruct us as to the natural history of
specific cells beyond genetic lineage
analysis. Alternatively, genetically engi-
neered mouse models present a useful
tool to study the natural history of tumor
hierarchies in an immune-competent
